Abstract
For more than 2 years, COVID-19 has been holding the world at awe with new waves of infections, novel mutants, and still limited (albeit improved) means to combat SARS-CoV-2-induced respiratory failure, the most common and fatal presentation of severe COVID-19. In the present perspective, we draw from the successes and-mostly-failures in previous acute respiratory distress syndrome (ARDS) work and the experiences from COVID-19 to define conceptual barriers that have so far hindered therapeutic breakthroughs in this deadly disease, and to open up new avenues of thinking and thus, ultimately of therapy.
Keywords: ARDS; COVID-19; endothelial; treatment; ventilator-induced lung injury.
All Keywords
【저자키워드】 COVID-19, Treatment, ARDS, endothelial, ventilator-induced lung injury., 【초록키워드】 therapy, Respiratory failure, severe COVID-19, infections, therapeutic, mutants, disease, acute respiratory distress, Ventilator-induced lung injury, Perspective, syndrome, to define, 【제목키워드】 Perspective,
【저자키워드】 COVID-19, Treatment, ARDS, endothelial, ventilator-induced lung injury., 【초록키워드】 therapy, Respiratory failure, severe COVID-19, infections, therapeutic, mutants, disease, acute respiratory distress, Ventilator-induced lung injury, Perspective, syndrome, to define, 【제목키워드】 Perspective,